BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25233003)

  • 1. Development of a high-throughput screening-compatible assay to identify inhibitors of the CK2α/CK2β interaction.
    Hochscherf J; Lindenblatt D; Steinkrüger M; Yoo E; Ulucan Ö; Herzig S; Issinger OG; Helms V; Götz C; Neundorf I; Niefind K; Pietsch M
    Anal Biochem; 2015 Jan; 468():4-14. PubMed ID: 25233003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand.
    Raaf J; Guerra B; Neundorf I; Bopp B; Issinger OG; Jose J; Pietsch M; Niefind K
    ACS Chem Biol; 2013 May; 8(5):901-7. PubMed ID: 23474121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction of CK2alpha and CK2beta, the subunits of protein kinase CK2, requires CK2beta in a preformed conformation and is enthalpically driven.
    Raaf J; Brunstein E; Issinger OG; Niefind K
    Protein Sci; 2008 Dec; 17(12):2180-6. PubMed ID: 18824508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
    Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
    Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of CK2β-Mimicking Peptides as Tools To Study the CK2α/CK2β Interaction in Cancer Cells.
    Lindenblatt D; Horn M; Götz C; Niefind K; Neundorf I; Pietsch M
    ChemMedChem; 2019 Apr; 14(8):833-841. PubMed ID: 30786177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2.
    Pietsch M; Viht K; Schnitzler A; Ekambaram R; Steinkrüger M; Enkvist E; Nienberg C; Nickelsen A; Lauwers M; Jose J; Uri A; Niefind K
    Bioorg Chem; 2020 Mar; 96():103608. PubMed ID: 32058103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Underlying mechanisms of cyclic peptide inhibitors interrupting the interaction of CK2α/CK2β: comparative molecular dynamics simulation studies.
    Zhou Y; Zhang N; Chen W; Zhao L; Zhong R
    Phys Chem Chem Phys; 2016 Apr; 18(13):9202-10. PubMed ID: 26974875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between CK2α and CK2β, the subunits of protein kinase CK2: thermodynamic contributions of key residues on the CK2α surface.
    Raaf J; Bischoff N; Klopffleisch K; Brunstein E; Olsen BB; Vilk G; Litchfield DW; Issinger OG; Niefind K
    Biochemistry; 2011 Feb; 50(4):512-22. PubMed ID: 21142136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the human protein kinase CK2 catalytic subunit CK2α' and interaction thermodynamics with the regulatory subunit CK2β.
    Bischoff N; Olsen B; Raaf J; Bretner M; Issinger OG; Niefind K
    J Mol Biol; 2011 Mar; 407(1):1-12. PubMed ID: 21241709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.
    Laudet B; Barette C; Dulery V; Renaudet O; Dumy P; Metz A; Prudent R; Deshiere A; Dideberg O; Filhol O; Cochet C
    Biochem J; 2007 Dec; 408(3):363-73. PubMed ID: 17714077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
    Bollacke A; Nienberg C; Borgne ML; Jose J
    J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protein kinase CK2(Andante) holoenzyme structure supports proposed models of autoregulation and trans-autophosphorylation.
    Schnitzler A; Olsen BB; Issinger OG; Niefind K
    J Mol Biol; 2014 May; 426(9):1871-82. PubMed ID: 24594356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical characterization of CK2alpha and alpha' paralogues and their derived holoenzymes: evidence for the existence of a heterotrimeric CK2alpha'-holoenzyme forming trimeric complexes.
    Olsen BB; Rasmussen T; Niefind K; Issinger OG
    Mol Cell Biochem; 2008 Sep; 316(1-2):37-47. PubMed ID: 18574672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary and secondary interactions between CK2alpha and CK2beta lead to ring-like structures in the crystals of the CK2 holoenzyme.
    Niefind K; Issinger OG
    Mol Cell Biochem; 2005 Jun; 274(1-2):3-14. PubMed ID: 16335523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eukaryotic translation-initiation factor eIF2beta binds to protein kinase CK2: effects on CK2alpha activity.
    Llorens F; Roher N; Miró FA; Sarno S; Ruiz FX; Meggio F; Plana M; Pinna LA; Itarte E
    Biochem J; 2003 Nov; 375(Pt 3):623-31. PubMed ID: 12901717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.
    Kufareva I; Bestgen B; Brear P; Prudent R; Laudet B; Moucadel V; Ettaoussi M; Sautel CF; Krimm I; Engel M; Filhol O; Borgne ML; Lomberget T; Cochet C; Abagyan R
    Sci Rep; 2019 Nov; 9(1):15893. PubMed ID: 31685885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CK2alpha/CK1alpha chimeras are sensitive to regulation by the CK2beta subunit.
    Jedlicki A; Allende CC; Allende JE
    Mol Cell Biochem; 2008 Sep; 316(1-2):25-35. PubMed ID: 18622690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
    Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
    Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of plant-specific N-terminal domain of maize CK2β1 subunit in CK2β functions and holoenzyme regulation.
    Riera M; Irar S; Vélez-Bermúdez IC; Carretero-Paulet L; Lumbreras V; Pagès M
    PLoS One; 2011; 6(7):e21909. PubMed ID: 21789193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface.
    Bestgen B; Belaid-Choucair Z; Lomberget T; Le Borgne M; Filhol O; Cochet C
    Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28165359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.